At Experto ReWell, we believe that better insights lead to better health. Continuous Glucose Monitors (CGMs) are advanced devices that continuously track blood glucose (blood sugar) levels in real time through a small sensor worn on the body. The data is instantly transmitted to a compatible device, such as a smartphone or reader, allowing users to stay informed throughout the day.

Over the years, CGM technology has become increasingly accurate, reliable, and widely accepted. Today, CGMs are considered an effective and transformative option for managing diabetes, helping individuals make informed decisions with confidence.

How CGMs Are Changing Diabetes Care

Innovations in CGM technology have significantly simplified daily diabetes management. Traditional methods often required multiple finger-stick tests every day. With a CGM, glucose monitoring and insulin management have evolved into a seamless digital experience—often requiring just a few taps on a mobile phone.

CGMs provide real-time glucose trends, alerting users when levels are rising or falling. This allows proactive action to prevent:

• Hypoglycemia (low blood glucose)

• Hyperglycemia (high blood glucose)

Continuous, real-time monitoring has led to improved outcomes and reduced risks of serious, potentially life-threatening complications. For many people living with diabetes, CGMs offer greater control, peace of mind, and an improved quality of life.

Access to CGM Technology

Despite their proven benefits and ease of use, access to CGMs is not yet universal. Many individuals—particularly those from underserved or lower-income communities, older populations, or those relying on limited healthcare coverage—still face barriers to accessing this life-changing technology.

At Experto ReWell, we believe that everyone living with diabetes deserves access to modern, evidence-based solutions. Equitable access to diabetes technology is essential for improving long-term health outcomes. Continued efforts from healthcare providers, policymakers, and organizations are needed to ensure broader and more consistent coverage for CGMs and other essential diabetes care tools.